Telomir Pharmaceuticals Closes TELI Acquisition, Secures Global Rights to Lead Drug Candidate
Telomir Pharmaceuticals completed its acquisition of TELI Pharmaceuticals, obtaining sole global rights to Telomir-1, a drug aimed at treating advanced breast cancer and targeting aging-related diseases, with a $1 million upfront payment and up to $4 million in milestones.
Telomir Pharmaceuticals (NASDAQ: TELO) announced the closing of its acquisition of TELI Pharmaceuticals, Inc., a move that consolidates global rights to its lead drug candidate, Telomir-1 (Telomir-Zn), and eliminates prior fragmentation of the asset across different territories. The transaction, approved by shareholders in March, includes $1.0 million in funding at closing and up to an additional $4.0 million in milestone-based contributions tied to clinical development progress.
The acquisition strengthens Telomir's position as it advances Telomir-Zn toward the clinic following a recent Investigational New Drug (IND) submission for the treatment of advanced and metastatic triple-negative breast cancer. The company plans to initiate a Phase 1/2 trial upon regulatory clearance while retaining flexibility for potential global partnerships. This development is significant because it gives Telomir full control over the commercialization and licensing of a drug that has shown promise in targeting fundamental mechanisms of cancer and aging.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to target fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The company's lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.
The acquisition is a strategic step for Telomir, as it now holds the keys to a drug candidate that could address multiple high-need areas. Triple-negative breast cancer is an aggressive form of breast cancer with limited treatment options, and Telomir-Zn's mechanism of action offers a novel approach by targeting cellular processes that go awry in cancer and aging. The company's ability to retain flexibility for partnerships could also accelerate development and bring the drug to patients faster.
For investors, the closing of this acquisition removes uncertainty around regional rights and provides a clearer path to clinical trials. The milestone-based funding structure aligns incentives with successful development, potentially reducing risk. More details are available in the company's newsroom at https://ibn.fm/TELO.